Molecular Formula | C26H44NNaO6S |
Molar Mass | 521.69 |
Melting Point | 165-175 °C |
Boling Point | 215 °C(lit.) |
Solubility | Soluble in water. |
Appearance | White to off-white powder |
Color | White to Off-White |
BRN | 3901205 |
Storage Condition | room temp |
Stability | Hygroscopic |
Sensitive | Easily absorbing moisture |
MDL | MFCD00036745 |
In vitro study | Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities. |
In vivo study | Taurochenodeoxycholic acid (0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2. Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats. |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
FLUKA BRAND F CODES | 3-10 |
HS Code | 29309090 |